Canadian association of gastroenterology clinical practice guidelines: The use of infliximab in Crohn's disease

Canadian Journal of Gastroenterology

Volumn 15, Issue 6, 2001, Pages 367-369

  Fedorak, R N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ARTICLE; BLADDER FISTULA; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; ENTEROCUTANEOUS FISTULA; GASTROENTEROLOGY; HUMAN; HYPERSENSITIVITY; INFECTION; INTESTINE OBSTRUCTION; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; PERINEUM; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS; VAGINA DISEASE; VALIDATION PROCESS;

EID: 0034926614     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/194506     Document Type: Article

References (4)

1. A critical approach to clinical practice guidelines
2. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor α for Crohn's disease
3. Infliximab for the treatment of fistulas in patients with Crohn's disease
4. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (infliximab) to maintain remission in Crohn's disease